Rasagiline monotherapy beneficial in early Parkinson's disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1373, 2003-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Rasagiline in Parkinson's Disease

By Oldfield Vicki   Keating Gillian M.   Perry Caroline M.  

CNS Drugs, Vol. 22, Iss. 1, 2008-01 ,pp. : 83-86

Adis International

Access to resources Recommend Favorite

Safety of rasagiline for the treatment of Parkinson's disease

By Perez-Lloret Santiago   Rascol Olivier  

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 633-643

Informa Healthcare

Access to resources Recommend Favorite

Pardoprunox monotherapy may provide benefit for patients with early-stage Parkinson's disease

By  

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting: An Economic Markov Model Evaluation

By Haycox Alan  

Drugs & Aging, Vol. 26, Iss. 9, 2009-09 ,pp. : 791-801

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting:: An Economic Markov Model Evaluation

By Kovacs Norbert   Janszky Jozsef   Nagy Ferenc  

Drugs & Aging, Vol. 28, Iss. 2, 2011-02 ,pp. : 161-162

Adis International

Access to resources Recommend Favorite